stockrow
Friday 6 November 2026
Export ALNY’s income statement to Excel — free account
Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
156.54
0.12
−0.08%
Follow ALNY
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 5 | 3 | 3 | 4 | 2 | 2 | 5 | 2 |
P/E ratio |
189.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
14.16 | 13.36 | 13.32 | 27.40 | 23.79 | 30.32 | 57.26 | 97.91 | 132.79 | 70.13 |
Altman Z-Score |
7.30 | 2.90 | 1.84 | 2.30 | 2.14 | 1.92 | 5.20 | 12.72 | 28.92 | 3.22 |
Altman Z″-Score (non-manufacturers) |
(0.11) | (2.60) | (3.07) | (4.01) | (2.17) | (1.67) | (2.40) | (0.09) | 8.26 | (0.91) |
P/FCF ratio |
112.99 | 0.00 | 580.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
241.50 | (317.31) | (817.18) | (215.38) | (133.79) | (121.36) | (64.21) | (48.74) | (115.87) | (42.22) |
Beneish M-Score |
(1.95) | (2.50) | (2.66) | (3.07) | (3.03) | 3.21 | (1.52) | (3.71) | (2.25) | (2.03) |
P/B ratio |
66.63 | 447.73 | 0.00 | 0.00 | 34.15 | 14.71 | 8.75 | 5.63 | 6.76 | 3.59 |
Price to Tangible BV |
66.63 | 447.73 | 0.00 | 0.00 | 34.15 | 14.71 | 8.75 | 5.63 | 6.76 | 3.59 |
EV/Sales |
13.65 | 12.62 | 12.54 | 26.27 | 21.71 | 26.91 | 51.53 | 83.83 | 114.32 | 60.02 |
EV/EBITDA |
90.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
96.71 | (3,412.86) | 220.14 | (50.34) | (28.56) | (21.56) | (40.67) | (11.16) | (26.85) | (9.20) |
EV/FCF |
108.90 | (666.08) | 546.65 | (44.43) | (25.52) | (19.35) | (27.05) | (9.11) | (21.11) | (7.60) |
Quick Ratio |
2.51 | 2.61 | 2.86 | 3.16 | 3.79 | 4.23 | 4.48 | 6.14 | 11.96 | 4.94 |
Current Ratio |
2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 |
Net Debt/EBITDA |
(3.41) | 13.89 | 6.22 | 1.59 | 2.84 | 2.23 | 1.42 | 1.32 | 3.40 | 1.16 |
Debt/Assets |
20.29% | 24.17% | 26.65% | 28.68% | 18.55% | 5.61% | 11.52% | 1.91% | 1.50% | 11.88% |
Debt/Equity |
1.28 | 15.27 | (4.63) | (6.43) | 1.15 | 0.19 | 0.19 | 0.02 | 0.02 | 0.16 |
Asset Turnover |
0.81 | 0.56 | 0.50 | 0.29 | 0.24 | 0.17 | 0.11 | 0.04 | 0.06 | 0.04 |
Operating CF/Net income |
1.67 | 0.03 | (0.24) | 0.48 | 0.75 | 0.72 | 0.31 | 0.74 | 0.78 | 0.75 |
Capex/Depreciation |
(1.05) | (0.60) | (1.15) | (1.62) | (0.85) | (0.95) | (2.58) | (8.32) | (8.76) | (4.27) |
Interest Coverage |
1.99 | (1.25) | (2.33) | (5.03) | (4.95) | (9.80) | (28.47) | (28.09) | (40.87) | (51.11) |
| 73.28% | 362.29% | 232.40% | (526.14%) | (106.31%) | (69.92%) | (64.66%) | (49.63%) | (36.54%) | (37.54%) | |
| 6.82% | (6.89%) | (11.94%) | (31.47%) | (24.19%) | (29.58%) | (44.64%) | (42.67%) | (30.14%) | (30.96%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (328.88%) | (205.47%) | (295.38%) | (59.85%) |
Return on Tangible Assets |
10.13% | (10.65%) | (17.33%) | (46.21%) | (32.61%) | (34.41%) | (49.55%) | (56.75%) | (27.23%) | (62.64%) |
Average Days of Receivables |
76.42 | 65.80 | 65.44 | 83.72 | 85.85 | 446.14 | 71.44 | 91.41 | 138.03 | 180.60 |
Research and Development Expense of Revenue |
35.54% | 50.09% | 54.94% | 85.12% | 93.83% | 132.86% | 298.12% | 674.72% | 434.46% | 810.86% |
Selling, General and Administrative Expense of Revenue |
32.60% | 43.39% | 43.52% | 74.29% | 73.51% | 119.39% | 217.98% | 510.44% | 221.73% | 189.47% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.38% | 12.10% | 12.12% | 22.23% | 19.63% | 28.38% | 79.56% | 210.59% | 103.23% | 160.16% |
Graham Net Nets |
0.00 | (0.03) | (0.04) | (0.04) | (0.01) | 0.02 | 0.06 | 0.13 | 0.13 | 0.10 |
Graham Number |
16.79 | 0.00 | 11.84 | 16.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.53% | (0.92%) | (1.81%) | (3.98%) | (4.25%) | (5.73%) | (7.07%) | (10.37%) | (4.10%) | (12.40%) |
Free Cash Flow Yield |
0.89% | (0.14%) | 0.17% | (2.16%) | (3.57%) | (4.59%) | (3.33%) | (9.40%) | (4.08%) | (11.26%) |
Revenue per Share |
28.35 | 17.61 | 14.64 | 8.53 | 7.13 | 4.29 | 2.01 | 0.74 | 0.99 | 0.55 |
Operating CF per Share |
4.00 | (0.07) | 0.83 | (4.45) | (5.42) | (5.35) | (2.55) | (5.59) | (4.23) | (3.59) |
Capex per Share |
(0.45) | (0.27) | (0.50) | (0.59) | (0.64) | (0.61) | (1.28) | (1.26) | (1.15) | (0.75) |
Free Cash Flow per Share |
3.55 | (0.33) | 0.34 | (5.04) | (6.06) | (5.96) | (3.83) | (6.85) | (5.38) | (4.35) |
Cash per Share |
22.20 | 21.11 | 19.53 | 18.02 | 20.56 | 16.30 | 14.06 | 10.78 | 18.67 | 7.32 |
Shareholders Equity per Share |
6.02 | 0.53 | (1.77) | (1.30) | 4.97 | 8.84 | 13.17 | 12.94 | 19.51 | 10.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.02 | 0.53 | (1.77) | (1.30) | 4.97 | 8.84 | 13.17 | 12.94 | 19.51 | 10.75 |
Free Cash Flow |
465.38 | (42.59) | 41.95 | (613.33) | (718.06) | (685.32) | (418.58) | (689.50) | (486.99) | (372.26) |
Working Capital |
2,584.31 | 2,109.01 | 2,014.91 | 1,924.33 | 2,112.87 | 2,029.51 | 1,363.27 | 1,021.20 | 1,620.49 | 540.18 |
Capital Expenditures |
(58.70) | (34.28) | (62.21) | (72.06) | (76.37) | (70.36) | (140.16) | (126.89) | (104.21) | (64.56) |
Net Current Asset Value |
(126.49) | (877.61) | (1,067.83) | (1,012.33) | (246.52) | 223.96 | 759.42 | 927.86 | 1,536.44 | 329.29 |
EV/EBIT |
101.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.07 | 0.09 | 0.14 | 0.64 | 1.69 | 1.16 | 1.37 |
Price to Operating Income |
104.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.11 | 0.10 | 0.08 | 0.18 | 0.16 | 0.13 | 0.05 | 0.07 | 0.13 |
Cash ROIC |
9.89% | (1.12%) | 1.29% | (20.10%) | (19.41%) | (22.24%) | (12.88%) | (28.54%) | (13.97%) | (21.94%) |
Accounts Receivable Turnover |
6.28 | 6.13 | 6.46 | 4.75 | 2.11 | 1.53 | 7.12 | 2.84 | 3.14 | 2.98 |
Accounts Payable Turnover |
6.68 | 4.49 | 4.04 | 1.97 | 2.24 | 1.53 | 0.46 | 0.04 | 0.00 | 0.00 |
Inventory Turnover |
8.46 | 3.86 | 2.85 | 1.57 | 1.73 | 1.19 | 0.62 | 0.05 | — | — |
Average Days of Payables |
61.94 | 99.80 | 65.28 | 212.09 | 191.24 | 243.01 | 726.50 | 12,094.02 | 0.00 | 0.00 |
Days of Inventory on Hand |
44.28 | 88.62 | 104.82 | 278.83 | 224.93 | 351.67 | 820.65 | 4,875.04 | — | — |
Average Receivables |
591.44 | 366.55 | 282.88 | 218.27 | 400.49 | 322.71 | 30.89 | 26.38 | 28.67 | 15.82 |
Average Payables |
102.07 | 71.97 | 76.81 | 85.76 | 62.70 | 50.93 | 54.80 | 44.03 | 41.41 | 35.63 |
Average Inventory |
80.61 | 83.83 | 109.05 | 107.66 | 80.78 | 65.78 | 40.21 | 40.00 | — | — |
Average Assets |
4,603.16 | 4,034.93 | 3,688.12 | 3,594.83 | 3,525.18 | 2,901.10 | 1,984.97 | 1,784.77 | 1,628.77 | 1,324.66 |
Average Common Equity |
428.13 | (76.78) | (189.43) | 214.99 | 802.23 | 1,227.47 | 1,370.33 | 1,534.20 | 1,343.33 | 1,092.47 |
Columns are period end dates · fundamentals updated 5 Nov 2026